Please login to the form below

Not currently logged in
Email:
Password:

Schering-Plough completes Organon BioSciences acquisition

US-based pharmaceutical company Schering-Plough has completed the acquisition of Dutch biotech Organon BioScience.

US-based pharmaceutical company Schering-Plough (S-P) has completed the acquisition of Dutch biotech Organon BioSciences (OBS).

S-P's agreement to acquire OBS was announced back in March 2007. The US company paid approximately EUR 11bn in cash for the company, which used to be a subsidiary of Dutch chemicals giant, Akzo Nobel.

OBS is comprised of the pharmaceutical company Organon and the animal health business Intervet. It also includes Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon.

Along with the acquisition S-P's gains the following OBS products: fertility treatment Follistim/Puregon, the muscle relaxant Zemuron/ Esmeron and the contraceptive implant Nuvaring/ Implanon.

For the animal health business, S-P gains the following vaccines for major animal species: Vista/Bovilis, a vaccine line for respiratory and reproductive infectious diseases in cattle; the poultry vaccine Nobilis; and Continuum/ Nobivac, a range of canine and feline vaccines. S-P will also gain the antiparasitic Safe-Guard/Panacur, the anti-infective COBACTAN, which is a broad-spectrum antibiotic for livestock species and horses, as well as the canine/ feline antidiabetes products Vetsulin/Caninsulin. S-P already has the animal health service, Homeagain, a US-based pet recovery network.

The CEO of S-P, Fred Hassan, said: "With Organon, we expand into two important prescription pharmaceutical franchises, women's health and central nervous system. These therapeutic areas add to our existing strengths in cardiovascular care, respiratory, immunology and oncology."

"We [also] increase our scale in Animal Health. This greatly increases the value we will bring to customers. We see this strong combined Animal Health unit as a key strategic part of our integrated business that will contribute to long-term high performance," concluded Hassan.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics